hyper prolactinemia

Hyperprolactinemia Dr. Ashraf Fouda F.E.B.O.G. Obs./Gyn. Consultant

[object Object],[object Object],[object Object],PROLACTIN

[object Object],[object Object],[object Object],[object Object],PROLACTIN

PROLACTIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],Pathophysiology

[object Object],[object Object],Pathophysiology

Manifestation of hyperprolactinemia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Manifestation of hyperprolactinemia

Hyperprolactinaemia ,[object Object],[object Object],[object Object],[object Object]

Causes of hyperprolactinemia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Idiopathic hyperprolactinemia

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Drug-induced hyperprolactinemia

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Drug-induced hyperprolactinemia

Hypothalamic Causes ,[object Object],[object Object]

Pituitary Causes ,[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],Empty sella syndrome

Hypothyroidism ,[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],Indications for Prolactin assay Not all hyperprolactinemic patients display galactorrhea and galactorrhea can be seen with normal prolactin level

Indications for sella evaluation ,[object Object],[object Object],[object Object],[object Object],[object Object]

Galactorrhea ,[object Object],[object Object]

[object Object],[object Object],Galactorrhea

If no obvious cause is identified or if a tumor is suspected, MRI should be performed. ,[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],If no obvious cause is identified or if a tumor is suspected, MRI should be performed.

Macroprolactinemia ,[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],Macroprolactinemia

Imaging Studies ,[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Management

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Medical treatment

[object Object],[object Object],[object Object],Medical treatment goals

Dopamine agonists ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Dopamine agonists NB: Parlodel  GH in healthy and  it in acromegalics 1 mg/week 75  g/day 0.1 mg/day 7.5 mg/d Maintenance 0.25-1 mg/TWW 25-300  g/day 0.1-0.2 mg/day 2.5-10 mg/day Dose Ergot Cabergoline (Dostinex) Ergot Quinagolide (Norprolac) Ergot Lisuride (Dopergine) Ergot Bromocriptine (Parlodel) Nature Agonist

Bromocriptine ,[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Bromocriptine

[object Object],[object Object],[object Object],[object Object],Bromocriptine

[object Object],[object Object],[object Object],Bromocriptine

[object Object],[object Object],Bromocriptine

Drugs safety in Pregnancy FDA system for classifying drugs based on potential to cause birth defects (1996) A B C D E No Risk Animal: No Risk Human: Not Adequate Animal: Toxicity Human: Not Adequate Human: Risk Human: Great Risk

Cabergoline ,[object Object],[object Object],[object Object]

[object Object],[object Object],Cabergoline

Surgical Care ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Radiotherapy ,[object Object],[object Object]

Key clinical recommendation ,[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],Key clinical recommendation

KEY POINTS ,[object Object],[object Object],[object Object]

[object Object],[object Object],KEY POINTS

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],KEY POINTS

[object Object],[object Object],[object Object],[object Object],KEY POINTS

[object Object],[object Object],[object Object],KEY POINTS

hyper prolactinemia

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (20)

Similar to hyper prolactinemia

Similar to hyper prolactinemia (20)

More from Karl Daniel, M.D.

More from Karl Daniel, M.D. (20)

hyper prolactinemia